



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/107325/>

Version: Accepted Version

Article:

Fernandes, J.S., Gentile, P., Martins, M. et al. (2016) Reinforcement of poly-L-lactic acid electrospun membranes with strontium borosilicate bioactive glasses for bone tissue engineering. *Acta Biomaterialia*, 44. pp. 168-177. ISSN: 1742-7061

<https://doi.org/10.1016/j.actbio.2016.08.042>

Article available under the terms of the CC-BY-NC-ND licence
(<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

1 **Reinforcement of Poly-L-lactic acid Electrospun Membranes with Strontium**

2 **Borosilicate Bioactive Glasses for Bone Tissue Engineering**

3 João S. Fernandes^{1,2}, Piergiorgio Gentile³, Margarida Martins^{1,2}, Nuno M. Neves^{1,2},

4 Cheryl Miller³, Aileen Crawford³ Ricardo A. Pires^{1,2,*}, Paul Hatton^{3,*}, Rui L. Reis^{1,2}

5 ¹ 3B's Research Group - Biomaterials, Biodegradables and Biomimetics, University of
6 Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and
7 Regenerative Medicine, AvePark, 4806-909 Taipas, Guimarães, Portugal

8 ² ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal

9 ³ Centre for Biomaterials and Tissue Engineering, School of Clinical Dentistry,
10 University of Sheffield, Claremont Crescent, Sheffield S10 2TA, United Kingdom

11
12 * Corresponding Authors:

13 Ricardo A. Pires. E-mail: rpires@dep.uminho.pt

14 Tel: +351 253 510 907

15 Fax: +351 253 510 909

16 and

17 Prof Paul V. Hatton. E-mail: paul.hatton@sheffield.ac.uk

18 Tel: +44 (0) 114 271 7938

19 Fax: +44 (0) 114 226 5484

20

21 **Abstract**

22 Herein, for the first time, we combined poly-L-Lactic acid (PLLA) with a strontium
23 borosilicate bioactive glass (BBG-Sr) using electrospinning to fabricate a composite
24 bioactive PLLA membrane loaded with 10 % (w/w) of BBG-Sr glass particles (PLLA-
25 BBG-Sr). The composites were characterised by scanning electron microscopy (SEM)
26 and microcomputer tomography (μ -CT), and the results showed that we successfully
27 fabricated smooth and uniform fibres (1 to 3 μ m in width) with a homogeneous
28 distribution of BBG-Sr microparticles (< 45 μ m). Degradation studies (in phosphate
29 buffered saline) demonstrated that the incorporation of BBG-Sr glass particles into the
30 PLLA membranes increased their degradability and water uptake with a continuous
31 release of cations. The addition of BBG-Sr glass particles enhanced the membrane's
32 mechanical properties (69 % higher Young modulus and 36 % higher tensile strength).
33 Furthermore, cellular *in vitro* evaluation using bone marrow-derived mesenchymal stem
34 cells (BM-MSCs) demonstrated that PLLA-BBG-Sr membranes promoted the
35 osteogenic differentiation of the cells as demonstrated by increased alkaline phosphatase
36 activity and up-regulated osteogenic gene expression (*Alpl*, *Sp7* and *Bglap*) in relation
37 to PLLA alone. These results strongly suggest that the composite PLLA membranes
38 reinforced with the BBG-Sr glass particles have potential as an effective biomaterial
39 capable of promoting bone regeneration.

40

41 **Key words:** Strontium borosilicate glasses, PLLA membranes, mineralisation,
42 osteogenic differentiation, BM-MSCs

43

44 **1. Introduction**

45 The development of biomaterials for guided bone tissue engineering (BTE) has been a
46 hot topic of research in recent years. Biomaterials can act as a short-term template in
47 which cells proliferate and deposit extracellular matrix (ECM), helping bone ingrowth
48 as a part of its regeneration process. A suitable biomaterial for BTE should present
49 appropriate mechanical properties that is able to withstand the mechanical stress
50 occurring at the lesion site and to support cell ingrowth as part of the bone formation
51 process. The capacity to shape the biomaterial substrate to fit exactly in the bone lesion
52 is of particular relevance, too [1, 2].

53 Electrospinning is a versatile technique that applies electrostatic forces to manufacture
54 ultrathin fibre meshes from melted polymers or polymer solutions. This methodology
55 has been used to obtain biomaterials composed by micro- or nano-fibres with high
56 surface areas and mechanical properties suitable for BTE by playing with its different
57 processing parameters [2, 3]. Furthermore, electrospun membranes closely mimic the
58 ECM promoting cell attachment and proliferation [4].

59 Poly-L-lactic acid (PLLA) is a biodegradable and biocompatible polymer, widely
60 investigated for BTE, specially due to the approval of different PLLA medical devices
61 for clinical use by the US Federal Food and Drug Administration (FDA) [5].
62 Furthermore, PLLA has appropriate flexibility and deformation capacity, and can be
63 processed by different techniques (e.g. melt, dry and wet spinning, as well as
64 electrospinning) [6-9]. However, PLLA is not commonly considered osteoinductive [4,
65 10]. Thus, in order to improve the biological performance of PLLA fibres, the
66 polymeric matrix can be combined with inorganic materials, such as bioactive glasses
67 (BG) and glass-ceramics, improving its osteoinductive potential [11, 12]. Moreover, the

68 PLLA degradation rate can be shaped by several different variables (e.g. chemical
69 structure and crystallinity of the polymer, size and shape of the final material), although,
70 the matching of the rate of degradation and the kinetics of the formation of new bone
71 tissue is still difficult to achieve [13, 14]. The addition of an inorganic phase allows a
72 better control of the degradation rate of the final PLLA-glass composite, which can be
73 used to manufacture a composite with a suitable degradation rate while progressively
74 being substituted by the new bone that is being formed [15].

75 Bioactive glasses (BGs) are a group of inorganic bioactive materials that are able to
76 form a bone-like hydroxyapatite (HA) layer on their surface capable to strongly bond to
77 hard and soft tissues [11, 16-18]. Immediately after the launch of the 45S5 Bioglass[®] in
78 the market (chemical composition by mol: $0.45\text{SiO}_2 \cdot 0.06\text{P}_2\text{O}_5 \cdot 0.245\text{Na}_2\text{O} \cdot$
79 0.245CaO) it became the gold standard for bioactive glass materials [16]. Subsequently,
80 a wide range of BGs based on the 45S5 composition have been developed and studied
81 for BTE [19, 20]. The addition of borate glass forming units is one approach that has
82 potential to lower melting temperatures while controlling bio-degradation and
83 increasing conversion rates to HA [21, 22]. Borosilicate-based BGs (BBGs) have
84 previously been studied as biomaterials and have shown relevant capacity as
85 osteointegrative antibacterial materials to be used in BTE [23, 24]. BBGs have been
86 also incorporated into scaffolds: Wang *et al.* [25] successfully incorporated copper
87 doped borosilicate glasses (BBG-Cu) into a polymeric scaffold for tissue engineering
88 purposes. They observed an improvement in the stability of the glass network and the
89 BBG-Cu promoted the angiogenesis in rat calvarial defects.

90 Moreover, in our previous studies we tested a BBG glass composition (e.g. molar ratio:
91 BBG-Sr: $0.05\text{Na}_2\text{O} \cdot 0.35\text{SrO} \cdot 0.20\text{B}_2\text{O}_3 \cdot 0.40\text{SiO}_2$) for their osteogenic capacity. We
92 found that the presence of BBG-Sr glass particles improved the osteogenic

93 differentiation of bone marrow mesenchymal stem cells (BM-MSCs) and induced also
94 the formation of mineralised tissue. We also demonstrated that demonstrated that BBG-
95 Sr, at concentrations ≥ 18 mg/mL it was able to eradicate *Pseudomonas aeruginosa*
96 bacterium [26]. Numerous reports have already associated Sr^{2+} with bone therapeutic
97 potential [19]. Depending on the concentration Sr^{2+} can exerts many effects on bone
98 metabolism at the tissue and cellular levels as well as in bone formation *in vivo* [27, 28].
99 For instance, Marie *et al.* [27] demonstrated strontium modulates bone cell function
100 (e.g. cell proliferation and differentiation) *in vitro* stimulating bone formation and
101 inhibiting bone resorption. Moreover, Hesaraki *et al.* showed that glasses doped with
102 Strontium promoted osteoblast proliferation and ALP activity when directly in culture
103 with cells [29]. For instance, Wu *et al.* [30] developed a strontium silicate glass which
104 promoted a high ALP activity in BM-MSC cell culture, which was associated with the
105 release of Sr^{2+} and silica. Also, Santocildes-Romero *et al.* [31] demonstrated that
106 strontium-substituted bioactive glasses promoted osteogenic differentiation of BM-
107 MSCs cultures in the presence of strontium -containing BGs. They showed an increased
108 expression of genes such as *Alpl* and *Bglap*. Moreover, Gentleman *et al.* [32] studied the
109 effect of the release of Si- and Sr-related chemical entities from PCL-SrBG scaffolds,
110 and they detected that the SrBG particles stimulated osteoblast proliferation and ALP
111 activity in relation to the SrBG-free PCL scaffold. Moreover, BM-MSCs are of special
112 interest due to their capacity to differentiation into different lineages (including
113 osteoblastic cells) with appropriate external stimuli and the fact that it is relatively easy
114 to isolate [33]. For that reason, BM-MSCs have received extensive attention as
115 promoters of tissue regeneration.

116 To our knowledge, the PLLA-BBG-Sr composite membranes fabricated by
117 electrospinning has not been achieved to-date. Therefore, we aimed to evaluate the

118 potential of PLLA-BBG-Sr composite membranes for BTE and bone regeneration.
119 Herein, we investigated the impact of the incorporation of BBG-Sr glass particles in
120 PLLA fibre meshes on their tensile strength and degradation. Moreover, we evaluated
121 the response of BM-MSCs in the presence of PLLA-BBG-Sr fibres, namely in what
122 regards their morphology, proliferation and ability to induce its differentiation.

123 **2. Experimental**

124 **2.1. Materials**

125 All chemicals used for the melt-quenched synthesis were reagent grade: boron oxide
126 (B_2O_3 , Alfa Aesar, Germany), calcium carbonate ($CaCO_3$, Sigma-Aldrich, UK), sodium
127 bicarbonate ($NaHCO_3$, Sigma-Aldrich, Australia), silica gel 60M (SiO_2 , Macherey-
128 Nagel, Germany), magnesium oxide (MgO , Sigma-Aldrich, UK) and strontium
129 carbonate ($SrCO_3$, Sigma-Aldrich, Australia). All the chemical reagents used for
130 electrospinning were reagent grade: PLLA with a L-lactide content of 99.6 % and an
131 average M_w of $69,000 \text{ g}\cdot\text{mol}^{-1}$ (Cargill Dow LLC, USA), dichloromethane (Sigma-
132 Aldrich, UK), and the anionic surfactant docusate sodium salt (Sigma-Aldrich, UK).

133 The BBGs were produced as described elsewhere. Briefly, the appropriate amounts of
134 SiO_2 , B_2O_3 , $NaHCO_3$, and $CaCO_3$ or MgO or $SrCO_3$, were accurately mixed with
135 ethanol (Sigma, Portugal) in a porcelain pestle and mortar, fully dried overnight and
136 transfer to a platinum crucible (ZGS platinum, Johnson Matthey, UK). Each batch (~ 50
137 g) was heated to $1450 \text{ }^\circ\text{C}$ in air for 1 hour and, subsequently, the melt was quickly
138 poured into an ice-water bath at $\sim 0 \text{ }^\circ\text{C}$ to form a glass frit. Afterwards, the glasses of
139 general formula $0.05Na_2O \cdot xMgO \cdot yCaO \cdot (0.35-x-y)SrO \cdot 0.20B_2O_3 \cdot 0.40SiO_2$ (molar
140 ratio, where $x, y = 0.35$ or 0.00 , and $x \neq y$) were ground into an Agate mortar (RETSCH,
141 Germany) to obtain microparticles and sieved to a size $<45 \text{ }\mu\text{m}$ to be homogeneously

142 incorporated in the polymeric matrix during the fabrication of the fibres. The density of
143 the BBGs was measured by a Multi pycnometer (Quantachrome Instruments, USA)
144 under helium at 110 °C using ~ 5 g of each sample.

145 **2.2. Glasses synthesis and membranes preparation**

146 **Electrospinning.** PLLA-BBG-Sr membranes were fabricated inside a fume hood
147 cabinet for safe solvent evaporation and in order to prevent that the turbulent air
148 interferes in the formation of the fibres. The PLLA concentration, the ratio of PLLA/
149 BBG-Sr and the process parameters (e.g. applied voltage, flow rate and distance from
150 the collector) were optimized in order to obtain uniform membrane of fibres. The final
151 electrospun membranes were fabricated using PLLA dissolved in dichloromethane (16
152 % w/v) where the BBGs microparticles were suspended (10 % w/w BBGs/PLLA).
153 Docusate sodium salt (1.2 % w/w relative to PLLA) was used to help the
154 homogenization of the solution avoiding the formation of agglomerates. The PLLA and
155 PLLA-BBG-Sr solutions were stirred overnight and sonicated 5 min before use to
156 remove air bubbles. The set up was mounted using a high voltage supplier, a syringe
157 pump (Baxter AS50) with a 20 gauge metal needle (Fisnar, New Jersey, USA) and a
158 conductive collector. The PLLA and PLLA-BBG-Sr solutions were drawn up into a 1
159 ml syringe (BD Plastipak, New Jersey, USA). The solutions were electrospun using 17
160 kV and a flow rate of 3 mL/h at a 19 cm distance between the collector and needle. The
161 electrospun membranes were dried in a fume hood, at room temperature, for 24 h,
162 collected and stored in a desiccator at room temperature.

163 **2.3. Characterisation of electro-spun membranes**

164 **2.3.1. Scanning electron microscopy (SEM)**

165 The Scanning Electron Microscopy (Leica Cambridge S360 microscope, equipped with
166 an energy dispersive spectrometer, UK) was used to assess the surface morphology of
167 the fabricated PLLA and PLLA-BBG-Sr membranes. Prior to the analysis, all the
168 scaffolds were sputter-coated with gold. The micrographs were acquired using a beam
169 energy of 5.0kV and working distance (WD) of ~ 5.2 mm.

170 **2.3.2. Micro-computed tomography (μ CT)**

171 Micro-computed tomography (μ -CT) was carried out on a high-resolution μ -CT scanner
172 (SkyScan1272, Bruker, Kontich, Belgium), using a pixel size of 9.8 μ m and integration
173 time of 160 ms. The X-ray source was set at 50 kV of energy and 200 μ A of current.
174 Approximately 400 projections were acquired over a rotation range of 180° with a
175 rotation step of 0.60°. Data sets were reconstructed using standardised cone-beam
176 reconstruction software (NRecon v1.6.10.2, SkyScan). The output format for each
177 sample was a series of 601 bitmap images (1224 \times 1224 pixels). 3D virtual models of
178 representative regions in the bulk of the scaffolds were created applying colour channel
179 thresholds and visualised using an image processing software (CTvox).

180 **2.3.3. Mechanical tests**

181 Tensile strength and modulus of the PLLA and PLLA-BBG-Sr membranes were
182 measured using a Uniaxial Universal Testing Machine (Instron 4505, USA) according
183 to the standard ASTM D 638. The membranes were cut into strips of 50 mm length, 10
184 mm width and 0.1 mm thickness. The tests were conducted using a 1 kN load cell, with
185 a gauge length of 20 mm and a crosshead speed of 5 mm.min⁻¹ until rupture. The tensile
186 force was taken from the stress-strain curves as the maximum stress hold by the
187 samples. Tensile modulus was estimated from the initial slope of the stress–strain curve

188 (between 0.5 % and 1 % strain) using the linear regression method. The average and
199 standard deviations were determined using 5 specimens per composition.

190 **2.3.4. Degradation assay**

191 The electrospun membranes (n= 3 per time point) were immersed in PBS (Sigma-
192 Aldrich, UK) at a ratio of 10:10 (membrane (mg): PBS (mL)) for 7, 14, 21, and 28 days
193 in a water-shaking bath at 60 rpm and 37 °C. Each immersion solution was filtered and
194 the pH measured (Crison Instruments, Spain). Inductive coupled plasma (ICP) analysis
195 was performed to determine the concentrations of Si, B and Sr in solution. The
196 absorption was measure at specific wavelengths ($\lambda= 251.611$ nm for Si, $\lambda= 249.773$ nm
197 for B and $\lambda= 407.771$ nm for Sr) and the concentrations were determined using
198 calibration curves obtained with standard solutions (Alfa Aesar) prior to the analysis of
199 the samples.

200 The membranes were removed from PBS, the excess surface water was removed and
201 the samples were immediately weighed. Afterwards, the samples were dried in the oven
202 at 37 °C, to constant weight, recording the final mass of the membranes. The water
203 uptake (WU) was calculated according to Eq. (1):

$$204 \quad WU(\%) = (m_{tp} - m_f)/m_f \times 100 \quad \text{Eq. (1)}$$

205 Where m_{tp} is the wet mass of the specimen at the specific time (days), and m_f is the final
206 mass after immersion and drying. The weight loss (WL) was calculated according to Eq.
207 (2):

$$208 \quad WL(\%) = (m_f - m_i)/m_i \times 100 \quad \text{Eq. (2)}$$

209 Where m_f is the mass of the dried membranes after its immersion in water, and m_i is the
210 mass of the dried membranes before immersion in PBS.

211 Thermogravimetric analysis (TGA; Q500, TA Instruments, USA) was also used to
212 quantify the changes in the weight (mass) of the membranes during the degradation
213 process. In addition, thermal analysis was performed to determine the amount of BBG-
214 Sr (non-combustible) glass particles that was compounded with PLLA to produce the
215 composite membranes. Experiments were performed in platinum pans, at a heating rate
216 of 40 k·min⁻¹ from 50 to 700 °C in an oxygen atmosphere.

217 **2.4. *In vitro* culture of BM-MSCs on electrospun membranes**

218 **2.4.1. Isolation and expansion of BM-MSCs**

219 Bone marrow mesenchymal stem cells (BM-MSCs) were isolated from bone marrow of
220 4-5 week-old male Wistar rats according to the method established by Maniatopoulos *et*
221 *al.* [34] and recently used by Santocildes-Romero [31]. BM-MSCs were expanded in
222 basal medium consisting of Dulbecco's modified Eagle's medium (DMEM; Sigma-
223 Aldrich, UK), supplemented with 100 U/mL penicillin (Sigma-Aldrich, UK) and 100
224 µg/mL streptomycin (Sigma-Aldrich, UK). Cells were cultured at 37 °C in an
225 atmosphere of 5 % CO₂.

226 **2.4.2. Culture of BM-MSCs**

227 Prior to the *in vitro* studies, BM-MSCs, at passage 2, were harvested and seeded at a
228 density of 3×10⁴ cells per membrane of Ø = 6.5 mm held in plastic inserts
229 (CellCrown™ 24, Scaffdex, UK). Cells were cultured for 7, 14 and 21 days under static
230 conditions. All scaffold conditions were cultured in basal and osteogenic differentiation
231 media (basal medium supplemented with 50 µg/mL L-ascorbic acid, 10 mM β-
232 glycerophosphate and 10⁻⁸ M dexamethasone).

233 **2.4.3. BM-MSCs proliferation, viability and morphology**

234 **Morphological evaluation of cultured cells:** After each time-point the cells cultured
235 on the membranes were washed with PBS and fixed with 4% formalin solution (0.5 mL)
236 for 15 min at room temperature (RT). The cells were then washed with PBS, containing
237 0.2 % Triton X, for 2 min. After the fixation and permeation steps, the cells were
238 washed again with PBS and stained with 4,6-diamidino-2-phenylindole dilactate (1:1000
239 DAPI, Sigma-Aldrich, UK) for 2 min at RT, and phalloidin-tetramethylrhodamine B
240 isothiocyanate (Sigma-Aldrich, UK) for 1 h at RT. Finally, the cells were washed and
241 observed using an Axioplan 2 imaging fluorescent microscope with a digital camera
242 QIC AM 12-bit (Zeiss, UK).

243 **Cell viability and proliferation (PrestoBlue® and PicoGreen® assays).** The
244 PrestoBlue® reagent (Fisher Scientific, UK) is a resazurin-based solution that is reduced
245 to resorufin by viable cells which can be detected flurometrically. The cell viability
246 assay was executed according to the manufacturer's instructions. In brief, the
247 PrestoBlue® reagent was added to a final concentration of 10 % to the cell culture
248 medium and the cultures incubated for 1 h at 37 °C. 200 µL samples of the culture
249 medium were removed and placed in 96-well plates and the resorufin fluorescence
250 quantified spectrophotometrically using a plate reader (Tecan Infinite M200). The
251 fluorescence was determined at an excitation wavelength of 560 nm and emission
252 wavelength of 590 nm. The metabolic activity was presented in fluorescence values and
253 compared with the control (cell cultured onto PLLA membranes under basal medium
254 conditions).

255 The PicoGreen® dsDNA reagent (Invitrogen, USA) is an ultrasensitive fluorescent
256 nucleic acid dye for quantification of double-stranded DNA (dsDNA) in solution. This
257 assay enables measurement of cell proliferation. After each culturing period, the cells
258 were washed with PBS and incubated at 37 °C for 3 h followed by a freezing step at -80

259 °C for overnight in ultra-pure water (1 mL) to ensure the cell lysis. Finally, the
 260 fluorescence was determined at an excitation wavelength of 485 nm and emission
 261 wavelength of 528 nm. The DNA concentration was presented in µg/mL and compared
 262 with the control (cell cultured onto PLLA membranes under basal medium conditions).

263 **2.4.3. Alkaline phosphatase quantification**

264 The concentration of alkaline phosphatase (ALP) was determined for all the cell culture
 265 time points, using the lysates used for the DNA quantification and the Alkaline
 266 Phosphatase, Diethanolamine Detection kit (Sigma-Aldrich, UK), which is based on the
 267 conversion of p-nitrophenyl phosphate (pNPP) to free p-nitrophenol by ALP. In brief, a
 268 buffered pNPP solution was prepared and equilibrated at 37 °C. Afterwards, 2 % (v/v)
 269 of sample or control lysate was added. Immediately after mixing the absorbance was
 270 read at 405 nm in a plate reader (Tecan Infinite M200) for ≈ 5 min. An ALP standard
 271 solution was used as control and buffer as blank. The units were calculated according to
 272 the following Eq. (3):

$$273 \quad \frac{(\Delta A_{405nm} / \text{min Test} - \Delta A_{405nm} / \text{min Blank}) \times df \times V_F}{18.5 \times V_E} \quad \text{Eq. (3)}$$

274 Where df = dilution factor; V_F = Volume of final solution; 18.5 = millimolar extinction
 275 coefficient of pNPP at 405 nm and V_E = Volume of samples/ALP standard solution.

276 **2.4.4. RNA isolation and real-time quantitative polymerase chain reaction (rtPCR)**

277 RNA was extracted with Tri-reagent (Sigma-Aldrich, UK) according to the
 278 manufacturer's instructions. The RNA concentration was determined by
 279 microspectrophotometry (NanoDrop 1000). The cDNA synthesis was performed using
 280 the qScript cDNA synthesis kit (Quanta BioSciences, VWR) with 100 ng of RNA
 281 template in a final volume of 20 µL. Cycling was as follows: 1 cycle at 22 °C, 5 min; 1

282 cycle at 42 °C, 30 min; 1 cycle at 85 °C, 5 min. The amplification of the target cDNA
 283 was performed using the PerfeCTa SYBR Green FastMix (Quanta BioSciences) with 1
 284 µL of cDNA, 200 nM of each primer (**Table 1**) in a final volume of 20 µL. Real time-
 285 PCR cycling was as follows: 1 cycle at 95 °C, 2 min; 44 cycles at 95 °C; 10 s at gene
 286 annealing temperature (**Table 1**); 30 s at 72 °C; followed by dissociation curve analysis.
 287 All the reactions were carried out on a PCR cycler Mastercycler Realplex (Hamburg,
 288 Germany). The transcripts expression data were normalized to the housekeeping gene
 289 glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) in each sample. The quantification
 290 was performed according to the Livak method ($2^{-\Delta\Delta Ct}$ method [35]), considering as
 291 calibrator at each time point the PLLA - basal medium for PLLA- osteogenic medium
 292 and PLLA-BBG-Sr basal medium for PLLA-BBG-Sr osteogenic medium (threshold =
 293 1).

294 **Table 1.** Primers used for qPCR


Gene	Primer sequence 5'-3' Forward/ reverse	Tm (°C)
Osteocalcin (<i>Bglap</i>)	CATCTATGGCACCACCGTTT AGAGAGAGGGAACAGGGAGG	60.0
Osteopontin (<i>Spp1</i>)	ATCTCACCATTC CGATGAATCT CAGTCCATAAGCCAAGCTATCA	60.0
Osterix (<i>Sp7</i>)	CACTGGCTCCTGGTTCTCTC CCACTCCTCCTCTTCGTGAG	60.0
Alkaline phosphatase (<i>Alpl</i>)	TGCCTTACCAACTCATTGTG ACGCGATGCAACACCACTC	57.4

295

296 **3. Results and discussion**

297 **3.1. Characterisation of electrospun membranes**

298 The PLLA and PLLA-BBG-Sr (10 % w/w BBG-Sr/PLLA) composite membranes were
299 successfully obtained by electrospinning. TGA analysis confirmed that we successfully
300 incorporated 10 % (w/w) of BBG-Sr microparticles in the PLLA fibres. The
301 morphology, microstructure and fibre integrity of the electrospun PLLA and PLLA-
302 BBG-Sr membranes was characterised by scanning electron microscopy (SEM) and
303 μ CT. Electrospun PLLA and PLLA-BBG-Sr membranes are composed of smooth and
304 uniform fibres. No large particles were detected (**Figure 1a** and **1c**), however, the
305 formation of small agglomerates in the membranes containing the BBG-Sr
306 microparticles was observed [36]. **Figure 1c** highlights in red circles the BBG-Sr
307 microparticles incorporated into the fibres. The homogeneous distribution of the BBG-
308 Sr microparticles in the PLLA-BBG-Sr membrane could be observed in the 2D virtual
309 model representatively obtained using an image processing software CTvox of μ CT
310 images (**Figure 1d**), in which the red colour represents the BBG-Sr microparticles
311 distributed into the composite membranes in green. As expected, the PLLA membranes
312 do not present any particles in their structure (**Figure 1b**).




313

314 **Figure 1.** SEM micrographs (a and c) and representative μ CT 2D images (b and d) of
 315 PLLA and PLLA-BBG-Sr membranes. The areas encompassed by red lines in (c) show
 316 particles incorporated into the fibres. In (b and d) PLLA fibres are represented in green
 317 and the BBG-Sr microparticles are represented in red.

318 The mechanical properties of the biomaterials are important in providing physical
 319 support for cell growth and migration matching those of the tissue at the site of
 320 implantation [37]. **Figure 2a** presents the stress–strain curves obtained for the PLLA
 321 and PLLA-BBG-Sr membranes under tensile load up to a strain of 50 %. The PLLA-
 322 BBG-Sr membranes showed the highest tensile strength (0.75 ± 0.7 MPa), when
 323 compared to the PLLA membranes (0.55 ± 0.6 MPa), indicating that the incorporation

324 of BBG-Sr reinforced the membranes. The same trend was observed for the Young's
325 modulus (**Figure 2b**), calculated from the initial linear slope of the stress-strain curves,
326 where the loading of BBG-Sr microparticles improved the modulus from 14.6 ± 3.8
327 MPa (PLLA) to 24.7 ± 5.3 MPa (PLLA-BBG-Sr). This might be due to an increase in
328 rigidity through the filler effect, in which the microparticles encumber the movement of
329 the polymer chains and the amount of extendable material in the membrane. On the
330 other hand, while the incorporation of the microparticles in PLLA-BBG-Sr membranes
331 can affect the tensile strength, where there is no interaction between fibres and particles.
332 The availability of cations derived from the incorporated microparticles may contribute
333 to the crosslinking of the carboxylic acid groups (that are present in the chain ends of
334 the PLLA) through the formation of carboxylates with the cations released from the
335 microparticles. These carboxylate cross-links induce the interlocking of the membranes,
336 resulting in an improvement of the Young modulus [38] As demonstrated by Thomas *et*
337 *al.* [39], small concentrations of nano hydroxyapatite (HA) resulted in a reinforcement
338 of PCL. It was observed by Jeong *et al.* [40] in an analogous way that the addition of
339 increasing concentrations of HA increasingly enhanced the mechanical properties of the
340 composite, namely their tensile strength and Young's modulus. Therefore, our results
341 support that, with the inclusion of BBG-Sr microparticles into the PLLA matrix, it is
342 possible to tune their mechanical properties, contribution to be a closer match of those
343 from the living tissue at the site of implantation.



344

345 **Figure 2.** (a) Stress–strain curves of PLLA and PLLA-BBG-Sr membranes and their
 346 respective (b) Young's modulus determined from the initial slope of the curves. The
 347 data was analysed by non-parametric statistics: Mann-Whitney test revealed a
 348 significance of $p < 0.05$ (*).


349

350 **3.2. Degradation of the electrospun membranes**

351 A biomaterial suitable for promoting bone regeneration in a tissue engineering
 352 perspective should present an appropriate biodegradability. The BTE concept is based
 353 on the substitution of the biomaterial by new bone. This requires that the degradation

354 rate of the biomaterial matches that of new bone formation, in order to occur a
355 progressive substitution of the biomaterial by the new bone tissue [15, 41]. The
356 degradation profiles of PLLA and PLLA-BBG-Sr membranes (**Figure 3**) were
357 evaluated from the weight loss and water uptake, as well as the release of chemical
358 species from the membranes and pH of the immersion solutions. The water uptake and
359 weight loss data showed differences between the PLLA and the PLLA-BBG-Sr
360 membranes (**Figure 3a and b**). Both membranes presented steady and continuous water
361 uptake and weight loss from week 2 to week 3. However, the PLLA-BBG-Sr
362 membranes presented a more pronounced ‘burst’ of weight loss during the first week.
363 The differences between the two membranes during this initial stage of degradation
364 might be attributed to the penetration of the PBS solution through the polymer/glass
365 interface and/or surface cracks that facilitated the degradation of the material and
366 enhanced the water uptake. Another possibility is related with a superficial hydrolytic
367 degradation generated by the leaching of chemical species from the glass particles [42,
368 43]. The pH measurements presented no significant variation of pH for both PLLA and
369 PLLA-BBG-Sr membranes over time. It was observed an increasing release of B, Si and
370 Sr from the PLLA-BBG-Sr membranes over time of immersion (**Figure 3c**). The
371 release of such chemical species can only be originated from the BBG-Sr
372 microparticles, confirming that the weight loss is mainly caused by the hydrolytic
373 degradation of the glass particles. During the last week of degradation (21 to 28 days) it
374 was also noticed an increase in the PLLA-BBG-Sr weight loss that is in line with the
375 reduction of glass content as determined by TGA tests (**Figure 3d**) and the increased
376 concentration of mainly B and Sr-containing chemical species, that were leached from
377 the glass particles to the immersion medium (detected by ICP). The increase on the
378 degradation is clear during the last week; however, the leaching observed by ICP during

379 the first 3 weeks is not corroborated by the TGA analysis. In this case, the presence of
380 phosphates from the solution buffer might generate a surface layer of strontium
381 phosphate that limits the mass exchange from the glass particles to the immersion
382 solution. In this case, the weight loss derived from the leaching of B, Si and Sr from the
383 glass particles is partially compensated by the deposition of phosphates. The fact that
384 the PLLA-BBG-Sr composite membranes lost twice the mass during the degradation
385 process suggests that the incorporation of BBG-Sr into PLLA fibres increased the
386 degradability and the degradation rate of the membranes, as well as the release of active
387 chemical species to the surrounding medium [15].



388

389 **Figure 3.** Degradation profile of the PLLA and PLLA-BBG-Sr membranes during 30
 390 day of degradation in PBS at 37 °C. (a and d) WU and WL of the PLLA and PLLA-
 391 BBG-Sr membranes; (c) release profiles of chemical species from the PLLA-BBG-Sr
 392 membranes; and (d) percentage of glass (w/w) in the studied membranes.


393

394 3.3. *In vitro* biological evaluation

395 Morphology, viability and proliferation of the BM-MSCs

396 Apart from the suitable chemical and physical properties of the biomaterial, it is also
 397 crucial to evaluate if they are cytotoxic. To this purpose, direct contact assays are

398 widely used as a preliminary screening for biomaterials [44]. Fluorescence microscopy
399 images (**Figure 4a**) show the morphology of BM-MSCs cultured in the presence of
400 PLLA and PLLA-BBG-Sr membranes in basal or osteogenic medium (**Figure 4a**, Basal
401 and Osteo, respectively). The attached BM-MSCs displayed a well-spread morphology
402 and several cell-to-cell contacts. As expected, the PrestoBlue[®] and PicoGreen[®] data
403 (**Figure 4b** and **4c**) demonstrated that the cells proliferated over the time course under
404 basal conditions, which is consistent with the morphology images (**Figure 4a**). There is
405 also an increase in their metabolic activity (day 7 versus day 21). However, under
406 osteogenic conditions BM-MSCs did not proliferate and exhibited an increase
407 in metabolic activity (day 7 versus day 21), which suggested the occurrence of
408 differentiation [8, 45]. PLLA and PLLA-BBG-Sr electrospun membranes were found to
409 be a non-cytotoxic support for BM-MSCs attachment and proliferation (**Figure 4**)
410 without any adverse effect caused by the addition of BBG-Sr particles. In addition, the
411 randomly distributed fibres and porous structure of electrospun membranes should
412 enable an efficient transfer of nutrients, as well as support suitable cell penetration into
413 the bulk of the membranes.




414

415 **Figure 4.** (a) Morphology, (b) metabolic activity and (c) proliferation of BM-MSCs
 416 cultured for 7, 14 and 21 days in basal (basal) or osteogenic medium (osteo), and in the
 417 presence of PLLA or PLLA-BBG-Sr. In the representative microscopy images (a) the
 418 nuclei of cells are stained in blue (DAPI) and the actin filaments are stained in green
 419 (Phalloidin). In Figure 4b and 4c, the results are expressed as means \pm standard
 420 deviation with $n = 3$ for each experimental data point. The data were analysed by non-
 421 parametric statistics: Kruskal-Wallis test, followed by a Dunn's Multiple Comparison
 422 test and were marked as: *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$. On the graphs the figure '1'
 423 represents the comparison with day 7 and the figure '2' represents the comparison with
 424 day 14.

425 3.3. Osteogenic differentiation markers

426 It has been demonstrated that the release of chemical species containing Si, B or Sr from
427 BBG-Sr glass particles could stimulate the osteoblast proliferation and differentiation.
428 The ALP activity is commonly related with functional activity of the bone-derived cells,
429 such as their osteogenic differentiation and the onset of mineralisation [36, 46]. In order
430 to execute a preliminary evaluation on the capacity of the PLLA-BBG-Sr membranes to
431 induce osteogenic differentiation, we cultured BM-MSCs onto them and quantified the
432 ALP activity after 7, 14 and 21 days (Figure 5b). SEM was also used to check for
433 mineral deposits and the mineralisation stage of the BM-MSCs (Figure 5a). In the SEM
434 micrographs it is possible to confirm that the BM-MSCs create a cell layer attached to
435 the PLLA and PLLA-BBG-Sr membranes. However, in the case of BM-MSCs cultured
436 under osteogenic conditions, formation of phosphate deposits at the later time points
437 (**Figure 5a**, day 21) were observed. In contrast, ALP activity (**Figure 5b**) increased
438 during the time of culture under osteogenic conditions, suggesting that the addition of
439 BBG-Sr microparticles increased the ALP expression levels. Therefore, the PLLA-
440 BBG-Sr membranes stimulated the BM-MSCs to initiate their osteogenic
441 differentiation. This stimulus is very likely to be related with the presence of the B, Si
442 and Sr chemical species leaching from the BBG-Sr glass particles to the surrounding
443 medium [47, 48], as also shown in the ICP data (**Figure 3a**). Comparatively, some
444 authors [31, 32] studied the effect of the release of Si and Sr chemical species from BG,
445 and found that they stimulate cell differentiation. Other authors have also demonstrated
446 improvements in cell differentiation and bone mineralisation by the addition of glass
447 particles into polymeric matrices [6, 36, 49]. As an example, Santocildes-Romero [9],
448 fabricated electrospun membranes incorporating 10% BGSr glass particles with
449 increasing Sr composition with no cytotoxic effects on at osteosarcoma cells; Rajzer
450 and co-workers [36] verified that the addition of 20% hydroxyapatite ceramic particles

451 into PLDL electrospun composites could direct HAp mineralisation in cell culture; Ren
 452 *et al.* [6] also showed that PCL-SrBG electrospun scaffolds enhanced the ALP activity
 453 of MC3T3-E1 cells in the presence of osteogenic media in comparison with the glass-
 454 free PCL scaffolds after 21 days of culture. Hence, the addition of BBG-Sr glass
 455 particles to PLLA fibres accelerates the BM-MSCs osteogenic differentiation (ALP
 456 activity, **Figure 5a**), in the presence of osteogenic media after 14 days of cell culture,
 457 showing an higher increase after 21 days of cell culture.



458

459 **Figure 5.** (a) Morphology/mineralisation (SEM micrographs) of BM-MSCs and their

460 (b) ALP activity after 7, 14 and 21 days of culture in the presence of PLLA and PLLA-


461 BBG-Sr, in basal (basal) or osteogenic medium (osteo). ALP results are expressed as
462 mean \pm standard deviation with n = 3 for each datapoint. The data was analysed by non-
463 parametric statistics: Kruskal-Wallis test, followed by a Dunn's Multiple Comparison
464 test. ** ($p < 0.01$); * ($p < 0.05$). The significance is in relation to cells cultured on PLLA (in
465 the absence of BBG-Sr glass particles) under the same culture conditions.

466

467 Complementary to the reported viability, proliferation and ALP activity data, the
468 differentiation level of BM-MSCs cultured onto PLLA and PLLA-BBG-Sr membranes
469 was assessed by quantitative PCR of selected bone-specific gene transcripts. In the
470 literature it is well described that osteogenic differentiation of BM-MSCs has three
471 phases: the proliferative phase, which is followed by the ECM synthesis and maturation,
472 and lastly the mineralisation phase [50, 51]. Therefore, in this study the osteogenic
473 potential of the cells was evaluated at day 14 and 21 using the expression pattern of the
474 representative osteogenic markers: *Alpl*, *Spp1*, *Bglap* and *Sp7* [8, 52]. The transcripts
475 expression data were normalized against the housekeeping gene *Gapdh* and the
476 quantification performed according to the Livak method ($2^{-\Delta\Delta Ct}$ method), considering
477 the PLLA (basal medium) as calibrator for PLLA (osteogenic medium) and PLLA-
478 BBG-Sr (basal medium) as calibrator for PLLA-BBG-Sr (osteogenic medium).
479 Commonly, *Alpl* acts as early marker of the osteoblastic phenotype. This gene
480 expression level is known to increase with the progression of osteoblastic differentiation
481 [53]. According to the gene expression data (**Figure 6a**) there is a significant up-
482 regulation of *Alpl* in the BM-MSCs cultured onto PLLA-BBG-Sr membranes at 14 and
483 21 days of culture in relation to BM-MSCs cultured onto PLLA membranes (all under
484 osteogenic medium). Again, the Ren et al. found the same *Alpl* gene up regulated in
485 MC3T3 cells cultured in PCL-SrBG membranes, but only after 21 days of culture.

486 These observations are consistent with the quantification of the ALP activity (**Figure**
487 **5b**), in which there was a significantly higher activity for the BM-MSCs cultured onto
488 PLLA-BBG-Sr (under osteogenic medium) after 14 days of culture, when compared
489 with the cells cultured onto PLLA [47, 48]. Regarding the maturation and
490 mineralization phase, we investigated the expression of the genes that encode two non-
491 collagenous proteins present with the ECM of bone, e.g. *Spp1* and *Bglap*. *Spp1* is a
492 protein found in bone, teeth, kidneys and epithelial lining tissue; consequently, *Spp1*
493 cannot be considered bone-specific, although it is associated to bone related functions
494 [8, 45]. The *Spp1* gene expression results (**Figure 6b**) showed that at 14 days of culture,
495 BM-MSCs cultured on PLLA presents a high *Spp1* expression, which might be related
496 with their important functions in cell adhesion, migration and survival [53]. The fact
497 that *Spp1* expression is significantly higher when cultured on PLLA membranes might
498 be a result of proliferation and cell spreading processes. On the other hand, *Bglap*,
499 which is the second most abundant protein present in bone, is exclusively secreted by
500 osteoblastic cells at the last stage of maturation [45, 53]. When cultured on PLLA-BBG-
501 Sr membranes, *Bglap* expression (**Figure 6c**) is significantly higher in relation to the
502 basal medium for 14 and 21 days of culture. This suggests that the combined effect of
503 the osteogenic factors and the dissolution products might be enhancing *Bglap* gene
504 expression, which may be an indicator of osteoblastic differentiation. This data is in
505 accordance with the report of Strobel *et al.* [54] showing that BM-MSCs, after 14 days
506 of exposure to cell culture medium containing nanoparticles of Sr-substituted Bioglass,
507 increased their *Bglap* expression. Finally, *Sp7* is a well-characterised osteoblast specific
508 gene and it is associated with the regulation of numerous other genes (e.g. osteocalcin,
509 osteopontin, bone sialoprotein), and is acknowledged as a late bone marker that plays a
510 key role in the differentiation of preosteoblasts into fully functioning osteoblasts [8, 53].

511 Our data at day 21 registered an increase of *Sp7* gene expression in the BM-MSCs
512 cultured on PLLA-BBG-Sr membranes (under osteogenic medium) in relation to the
513 same cells cultured on the same membranes but under basal medium, as well as the cells
514 cultured onto PLLA (under osteogenic and basal medium). These observations are
515 consistent with the overexpression of the other monitored gene *Alpl* and their protein
516 expression (ALP) for PLLA-BBG-Sr membrane [55]. In fact, Isaac *et al.* [56]
517 demonstrated that the addition of strontium to bioactive glass particles resulted in a
518 significant up-regulation of Runx2 and Osterix of osteoblastic cells. In summary, the
519 detected overexpression of *Alpl*, *Bglap* and *Sp7* genes in cells cultured onto PLLA-
520 BBG-Sr membranes show that the incorporation of BBG-Sr glass particles into the
521 PLLA membranes promotes the osteogenic differentiation of BM-MSCs [47].



522

523 **Figure 6.** Relative gene expression profile of BM-MSCs cultured onto PLLA and
 524 PLLA-BBG-Sr membranes during 14 and 21 days. Selected genes: *Alpl*, osteogenic
 525 mineralisation initiators (a); *Spp1* (b) and *Bglap* (c), extracellular matrix; *Sp7*,
 526 transcription factors. The transcripts' expression data were normalized against the
 527 housekeeping gene *Gapdh* and the quantification performed according to the Livak
 528 method ($2^{-\Delta\Delta C_t}$ method). For each timepoint it was used: the calibrator PLLA (in basal
 529 medium) for the experiments with PLLA (in osteogenic medium); and the calibrator
 530 PLLA-BBG-Sr (in basal medium) for the experiments with PLLA-BBG-Sr (in
 531 osteogenic medium). In all the cases the calibrator is represented as a dashed line
 532 (threshold = 1). The results are expressed as mean \pm standard deviation with n = 3 for
 533 each bar. The data was analysed by non-parametric statistics: Kruskal-Wallis test,

534 followed by a Dunn's Multiple Comparison test and differences were considered: ***
535 $p < 0.001$; ** $p < 0.01$; and * $p < 0.05$. *a* denotes significant differences in relation to cells
536 cultured in basal medium (PLLA or PLLA-BBG-Sr); *b* denotes significant differences in
537 relation to cell cultured onto PLLA in osteogenic medium.

538 **4. Conclusion**

539 Bioactive membranes of PLLA-BBG-Sr composites were successfully prepared using
540 electrospinning. The μ CT data evidenced that BBG-Sr microparticles were
541 homogeneously incorporated into the fibres and the membrane structure. Our data
542 indicated that, the addition of BBG-Sr into the PLLA matrix improved the *in vitro* water
543 uptake and degradability of the membranes. Moreover, the incorporation of the BBG-Sr
544 microparticles improved the mechanical properties of the membranes, namely in their
545 Young modulus and tensile strength. The *in vitro* biological evaluation confirmed that
546 both PLLA and PLLA-BBG-Sr membranes are able to promote the attachment of BM-
547 MSCs, without any cytotoxic effects. Furthermore, the addition of BBG-Sr
548 microparticles to the PLLA membranes increased the ALP activity (under osteogenic
549 conditions), as well as the BM-MSCs osteogenic differentiation as shown by up-
550 regulation of *Alpl*, *Sp7* and *Bglap* gene expression *in vitro*. The present work suggests
551 that the composite of PLLA membranes and BBG-Sr microparticles can be used as a
552 strategy to prepare bioactive composite membranes for bone regeneration.

553 **Acknowledgements**

554 The authors gratefully acknowledge financial support from Portuguese Foundation for
555 Science and Technology (Ph.D. grant BD/73162/2010), the European Union's Seventh
556 Framework Programme (FP7/2007–2013) under Grant No. REGPOT-CT2012-31633-
557 POLARIS. This work was also supported by the European Research Council grant

558 agreement ERC-2012-ADG-20120216-321266 for the project ComplexiTE and UK
559 EPSRC Centre for Innovative Manufacturing of Medical Devices-MeDe Innovation
560 (EPSRC grant EP/K029592/1).

561

562

563 **5. References**

- 564 [1] Zhao S, Zhu M, Zhang J, Zhang Y, Liu Z, Zhu Y, Zhang, Changqing. Three dimensionally
565 printed mesoporous bioactive glass and poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)
566 composite scaffolds for bone regeneration. *Journal of Materials Chemistry B* 2014;2:6106-18.
- 567 [2] Jiang T, Carbone EJ, Lo KWH, Laurencin CT. Electrospinning of polymer nanofibers for tissue
568 regeneration. *Progress in Polymer Science* 2015;46:1-24.
- 569 [3] Gentile P, Chiono V, Carmagnola I, Hatton PV. An Overview of Poly(lactic-co-glycolic) Acid
570 (PLGA)-Based Biomaterials for Bone Tissue Engineering. *International Journal of Molecular*
571 *Sciences* 2014;15:3640-59.
- 572 [4] Sui G, Yang X, Mei F, Hu X, Chen G, Deng X, Ryu, Seungkon. Poly-L-lactic
573 acid/hydroxyapatite hybrid membrane for bone tissue regeneration. *Journal of Biomedical*
574 *Materials Research Part A* 2007;82A:445-54.
- 575 [5] Madhavan Nampoothiri K, Nair NR, John RP. An overview of the recent developments in
576 polylactide (PLA) research. *Bioresource Technology* 2010;101:8493-501.
- 577 [6] Ren J, Blackwood KA, Doustgani A, Poh PP, Steck R, Stevens MM, Woodruff, Maria A.. Melt-
578 electrospun polycaprolactone-strontium substituted bioactive glass scaffolds for bone
579 regeneration. *Journal of Biomedical Materials Research Part A* 2013;n/a-n/a.
- 580 [7] Gupta B, Revagade N, Hilborn J. Poly(lactic acid) fiber: An overview. *Progress in Polymer*
581 *Science* 2007;32:455-82.
- 582 [8] Martins A, Duarte ARC, Faria S, Marques AP, Reis RL, Neves NM. Osteogenic induction of
583 hBMSCs by electrospun scaffolds with dexamethasone release functionality. *Biomaterials*
584 2010;31:5875-85.
- 585 [9] Santocildes-Romero ME, Goodchild RL, Hatton PV, Crawford A, Reaney IM, Miller CA.
586 Preparation of Composite Electrospun Membranes Containing Strontium-Substituted Bioactive
587 Glasses for Bone Tissue Regeneration. *Macromolecular Materials and Engineering* 2016.
- 588 [10] Haimi S, Suuriniemi N, Haaparanta A-M, Ellä V, Lindroos B, Huhtala H, et al. Growth and
589 Osteogenic Differentiation of Adipose Stem Cells on PLA/Bioactive Glass and PLA/ β -TCP
590 Scaffolds. *Tissue Engineering Part A* 2008;15:1473-80.
- 591 [11] Bhakta S, Faira P, Salata L, de Oliveira Neto P, Miller C, van Noort R. Determination of
592 relative in vivo osteoconductivity of modified potassium fluorrichterite glass-ceramics
593 compared with 45S5 bioglass. *Journal of Materials Science: Materials in Medicine*
594 2012;23:2521-9.
- 595 [12] Hench L. The story of Bioglass. *Journal of Materials Science: Materials in Medicine*
596 2006;17:967-78.
- 597 [13] Mofokeng JP, Luyt AS. Morphology and thermal degradation studies of melt-mixed
598 poly(lactic acid) (PLA)/poly(ϵ -caprolactone) (PCL) biodegradable polymer blend
599 nanocomposites with TiO₂ as filler. *Polymer Testing* 2015;45:93-100.
- 600 [14] Carrasco F, Pagès P, Gámez-Pérez J, Santana OO, Maspoch ML. Processing of poly(lactic
601 acid): Characterization of chemical structure, thermal stability and mechanical properties.
602 *Polymer Degradation and Stability* 2010;95:116-25.
- 603 [15] Niu Y, Guo L, Liu J, Shen H, Su J, An X. Bioactive and degradable scaffolds of the
604 mesoporous bioglass and poly(l-lactide) composite for bone tissue regeneration. *Journal of*
605 *Materials Chemistry B* 2015;3:2962-70.
- 606 [16] Hench LL. Bioceramics: From Concept to Clinic. *Journal of the American Ceramic Society*
607 1991;74:1487-510.
- 608 [17] Barros AAA, Alves A, Nunes C, Coimbra MA, Pires RA, Reis RL. Carboxymethylation of ulvan
609 and chitosan and their use as polymeric components of bone cements. *Acta Biomaterialia*
610 2013;9:9086-97.
- 611 [18] Gomes FO, Pires RA, Reis RL. Aluminum-free glass-ionomer bone cements with enhanced
612 bioactivity and biodegradability. *Materials Science and Engineering: C* 2013;33:1361-70.

- 613 [19] Rabiee SM, Nazparvar N, Azizian M, Vashae D, Tayebi L. Effect of ion substitution on
614 properties of bioactive glasses: A review. *Ceram Int* 2015;41:7241-51.
- 615 [20] Rahaman MN, Day DE, Sonny Bal B, Fu Q, Jung SB, Bonewald LF. Bioactive glass in tissue
616 engineering. *Acta Biomaterialia* 2011;7:2355-73.
- 617 [21] Pan HB, Zhao XL, Zhang X, Zhang KB, Li LC, Li ZY. Strontium borate glass: potential
618 biomaterial for bone regeneration. *J R Soc Interface* 2010;7:1025-31.
- 619 [22] Huang W, Day D, Kittiratanapiboon K, Rahaman M. Kinetics and mechanisms of the
620 conversion of silicate (45S5), borate, and borosilicate glasses to hydroxyapatite in dilute
621 phosphate solutions. *Journal of Materials Science: Materials in Medicine* 2006;17:583-96.
- 622 [23] Pires RA, Abrahams I, Nunes TG, Hawkes GE. Multinuclear magnetic resonance studies of
623 borosilicate glasses for use in glass ionomer cements: incorporation of CaO and Al₂O₃. *Journal*
624 *of Materials Chemistry* 2006;16:2364-73.
- 625 [24] Pires RA, Abrahams I, Nunes TG, Hawkes GE. The role of alumina in aluminoborosilicate
626 glasses for use in glass-ionomer cements. *Journal of Materials Chemistry* 2009;19:3652-60.
- 627 [25] Wang H, Zhao S, Xiao W, Xue J, Shen Y, Zhou J. Influence of Cu doping in borosilicate
628 bioactive glass and the properties of its derived scaffolds. *Materials Science and Engineering: C*
629 *2016;58:194-203.*
- 630 [26] Fernandes JS, Martins M, Neves NM, Fernandes MHFV, Reis RL, Pires RA. Intrinsic
631 Antibacterial Borosilicate Glasses for Bone Tissue Engineering Applications. *ACS Biomaterials*
632 *Science & Engineering* 2016.
- 633 [27] Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of Action and Therapeutic Potential of
634 Strontium in Bone. *Calcified Tissue International* 2001;69:121-9.
- 635 [28] Hoppe A, Güldal NS, Boccaccini AR. A review of the biological response to ionic dissolution
636 products from bioactive glasses and glass-ceramics. *Biomaterials* 2011;32:2757-74.
- 637 [29] Hesaraki S, Gholami M, Vazehrad S, Shahrabi S. The effect of Sr concentration on
638 bioactivity and biocompatibility of sol-gel derived glasses based on CaO-SrO-SiO₂-P₂O₅
639 quaternary system. *Materials Science and Engineering: C* 2010;30:383-90.
- 640 [30] Wu C, Fan W, Gelinsky M, Xiao Y, Simon P, Schulze R. Bioactive SrO-SiO₂ glass with well-
641 ordered mesopores: Characterization, physiochemistry and biological properties. *Acta*
642 *Biomaterialia* 2011;7:1797-806.
- 643 [31] Santocildes-Romero ME, Crawford A, Hatton PV, Goodchild RL, Reaney IM, Miller CA. The
644 osteogenic response of mesenchymal stromal cells to strontium-substituted bioactive glasses.
645 *Journal of Tissue Engineering and Regenerative Medicine* 2015;9:619-31.
- 646 [32] Gentleman E, Fredholm YC, Jell G, Lotfibakhshaiesh N, O'Donnell MD, Hill RG. The effects
647 of strontium-substituted bioactive glasses on osteoblasts and osteoclasts in vitro. *Biomaterials*
648 *2010;31:3949-56.*
- 649 [33] Brooke G, Cook M, Blair C, Han R, Heazlewood C, Jones B. Therapeutic applications of
650 mesenchymal stromal cells. *Seminars in Cell & Developmental Biology* 2007;18:846-58.
- 651 [34] Maniopoulos C, Sodek J, Melcher AH. Bone formation in vitro by stromal cells obtained
652 from bone marrow of young adult rats. *Cell Tissue Res* 1988;254:317-30.
- 653 [35] Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time
654 Quantitative PCR and the 2- $\Delta\Delta$ CT Method. *Methods* 2001;25:402-8.
- 655 [36] Rajzer I, Menaszek E, Kwiatkowski R, Chrzanowski W. Bioactive nanocomposite
656 PLDL/nano-hydroxyapatite electrospun membranes for bone tissue engineering. *J Mater Sci:*
657 *Mater Med* 2014;25:1239-47.
- 658 [37] Chan BP, Leong KW. Scaffolding in tissue engineering: general approaches and tissue-
659 specific considerations. *European Spine Journal* 2008;17:467-79.
- 660 [38] Liang S-L, Cook WD, Thouas GA, Chen Q-Z. The mechanical characteristics and in vitro
661 biocompatibility of poly(glycerol sebacate)-Bioglass[®] elastomeric composites. *Biomaterials*
662 *2010;31:8516-29.*

663 [39] Thomas V, Jagani S, Johnson K, Jose MV, Dean DR, Vohra YK, et al. Electrospun Bioactive
664 Nanocomposite Scaffolds of Polycaprolactone and Nanohydroxyapatite for Bone Tissue
665 Engineering. *Journal of Nanoscience and Nanotechnology* 2006;6:487-93.

666 [40] Jeong SI, Ko EK, Yum J, Jung CH, Lee YM, Shin H. Nanofibrous Poly(lactic
667 acid)/Hydroxyapatite Composite Scaffolds for Guided Tissue Regeneration. *Macromolecular*
668 *Bioscience* 2008;8:328-38.

669 [41] Shakya AK, Holmdahl R, Nandakumar KS, Kumar A. Polymeric cryogels are biocompatible,
670 and their biodegradation is independent of oxidative radicals. *Journal of Biomedical Materials*
671 *Research Part A* 2014;102:3409-18.

672 [42] Liao G, Jiang S, Xu X, Ke Y. Electrospun aligned PLLA/PCL/HA composite fibrous
673 membranes and their in vitro degradation behaviors. *Materials Letters* 2012;82:159-62.

674 [43] Navarro M, Ginebra MP, Planell JA, Barrias CC, Barbosa MA. In vitro degradation behavior
675 of a novel bioresorbable composite material based on PLA and a soluble CaP glass. *Acta*
676 *Biomaterialia* 2005;1:411-9.

677 [44] Zonari A, Novikoff S, Electo NRP, Breyner NM, Gomes DA, Martins A. Endothelial
678 Differentiation of Human Stem Cells Seeded onto Electrospun
679 Polyhydroxybutyrate/Polyhydroxybutyrate-Co-Hydroxyvalerate Fiber Mesh. *PLoS ONE*
680 2012;7:e35422.

681 [45] Amorim S, Martins A, Neves NM, Reis RL, Pires RA. Hyaluronic acid/poly-L-lysine bilayered
682 silica nanoparticles enhance the osteogenic differentiation of human mesenchymal stem cells.
683 *Journal of Materials Chemistry B* 2014;2:6939-46.

684 [46] Marie PJ, Fromigué O. Osteogenic differentiation of human marrow-derived mesenchymal
685 stem cells. *Regenerative Medicine* 2006;1:539-48.

686 [47] Peng S, Zhou G, Luk KDK, Cheung KMC, Li Z, Lam WM. Strontium Promotes Osteogenic
687 Differentiation of Mesenchymal Stem Cells Through the Ras/MAPK Signaling Pathway. *Cellular*
688 *Physiology and Biochemistry* 2009;23:165-74.

689 [48] Yang F, Yang D, Tu J, Zheng Q, Cai L, Wang L. Strontium Enhances Osteogenic
690 Differentiation of Mesenchymal Stem Cells and In Vivo Bone Formation by Activating
691 Wnt/Catenin Signaling. *STEM CELLS* 2011;29:981-91.

692 [49] Kim H-W, Lee H-H, Knowles JC. Electrospinning biomedical nanocomposite fibers of
693 hydroxyapatite/poly(lactic acid) for bone regeneration. *Journal of Biomedical Materials*
694 *Research Part A* 2006;79A:643-9.

695 [50] Reis AMS, Ribeiro LGR, Ocarino NdM, Goes AM, Serakides R. Osteogenic potential of
696 osteoblasts from neonatal rats born to mothers treated with caffeine throughout pregnancy.
697 *BMC Musculoskeletal Disorders* 2015;16:1-11.

698 [51] zur Nieden NI, Kempka G, Ahr HJ. In vitro differentiation of embryonic stem cells into
699 mineralized osteoblasts. *Differentiation* 2003;71:18-27.

700 [52] Munisso MC, Kang J-H, Tsurufuji M, Yamaoka T. Cilomilast enhances osteoblast
701 differentiation of mesenchymal stem cells and bone formation induced by bone
702 morphogenetic protein 2. *Biochimie* 2012;94:2360-5.

703 [53] Ashammakhi N, Reis R, Chiellini E. Chapter 13: Genes and Proteins Involved in the
704 Regulation of Osteogenesis. In: G. K, S. C, N. A, editors. *Topics in Tissue Engineering* 2007.

705 [54] Strobel LA, Hild N, Mohn D, Stark WJ, Hoppe A, Gbureck U. Novel strontium-doped
706 bioactive glass nanoparticles enhance proliferation and osteogenic differentiation of human
707 bone marrow stromal cells. *Journal of Nanoparticle Research* 2013;15:1-9.

708 [55] Tu Q, Valverde P, Chen J. Osterix enhances proliferation and osteogenic potential of bone
709 marrow stromal cells. *Biochemical and biophysical research communications* 2006;341:1257-
710 65.

711 [56] Isaac J, Nohra J, Isaac J, Jallot E, JNedelec J, Berdal A, et al. Effects of strontium-doped
712 bioactive glass on the differentiation of cultured osteogenic cells. *European Cells and Materials*
713 2011;21:130-43.